Latest news about Auro Laboratories
Auro Laboratories
248.00
-0.80(-0.32%)
Company Performance:
View Company Insights1D-0.32%
1M-2.07%
6M+13.42%
1Y-5.79%
5Y+33.30%
More news about Auro Laboratories
05Feb 26
Auro Laboratories Reports Strong Q3FY26 Results with 206% Revenue Growth
Auro Laboratories Limited reported exceptional Q3FY26 results with revenue from operations surging 206% to ₹939.30 lakhs and net profit jumping to ₹195.18 lakhs from ₹5.10 lakhs in Q3FY25. The nine-month performance also remained strong with revenue growing 76% to ₹2,090.56 lakhs and net profit increasing 129% to ₹266.18 lakhs. The Board approved these results on February 5, 2026, following audit committee review and statutory auditor's limited review.
28Jan 26
Auro Laboratories Limited Schedules Board Meeting on February 05, 2026 for Q3FY26 Financial Results
Auro Laboratories Limited has scheduled a board meeting for February 05, 2026, to consider and approve unaudited financial results for the quarter ended December 31, 2025, along with the Limited Review Report. The company has maintained trading window restrictions for designated persons and their immediate relatives, which will continue until 48 hours after the board meeting concludes. This notification complies with SEBI Regulation 29(1)(a) requirements and has been communicated to BSE Limited under security code 530233.
13Nov 25
Auro Laboratories Secures WHO-GMP Certification for API Manufacturing Facility
Auro Laboratories Limited has successfully completed a WHO inspection at its API manufacturing facility in MIDC Tarapur, Maharashtra. The company received a WHO-GMP Certificate from the Food & Drug Administration, Maharashtra, valid until September 30, 2028, for its bulk drugs manufacturing operations. This certification demonstrates Auro Laboratories' adherence to high manufacturing standards and may open up new global market opportunities.
13Nov 25
Auro Laboratories Reports Quarterly Loss of Rs 71.58 Lakhs
Auro Laboratories Limited reported a net loss of Rs 71.58 lakhs for Q2 FY2026, up from Rs 10.55 lakhs loss in Q1. Revenue from operations increased to Rs 883.67 lakhs from Rs 217.42 lakhs in the previous quarter. Total income rose to Rs 981.25 lakhs, but expenses also increased significantly to Rs 809.27 lakhs. The company's total assets stood at Rs 11,077.34 lakhs with total equity of Rs 4,357.84 lakhs. On a positive note, Auro Laboratories received a WHO-GMP Certificate for its API manufacturing facility, valid until September 30, 2028.
23Aug 25
Auro Laboratories Announces Key Management Changes and Auditor Appointments
Auro Laboratories Ltd has made significant changes in its management and auditing structure. The company appointed M/s B.L. Dasharda & Associates as new Statutory Auditors for five years, replacing M/s Kothari Jain & Associates. Mrs. Kavita Vijayakant Sharma was re-appointed as Non-Executive Independent Director for a second five-year term. Ms. Padma Tapariya was named new Company Secretary and Compliance Officer. M/s GMJ & Associates were appointed as Secretarial Auditors for five years. The company's 36th Annual General Meeting is scheduled for September 25, 2025, to be held via video conferencing.
Industry Peers
Sun Pharmaceutical
Divis Laboratories
Torrent Pharmaceuticals
Cipla
Lupin
Zydus Life Science
Mankind Pharma
Dr Reddys Laboratories
Aurobindo Pharma
Laurus Labs
1,921.40
(-0.73%)
6,938.50
(+1.50%)
4,951.10
(+1.01%)
1,426.70
(-0.88%)
2,492.60
(-0.15%)
1,131.30
(-1.69%)
2,507.50
(-0.70%)
1,234.50
(-0.79%)
1,549.30
(-0.98%)
1,558.60
(+1.35%)
we are part of Raise Financial Services
built with love
for indians who love to invest & trade
Market Community
Follow us on
